| S8275 |
Tomivosertib (eFT508)
|
Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. Tomivosertib (eFT-508) inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
|
-
Nat Commun, 2025, 16(1):7853
-
Nat Commun, 2024, 15(1):9755
-
J Clin Invest, 2024, 134(16)e168393
|
|
| S7421 |
CGP 57380
|
CGP 57380 is a potent MNK1 inhibitor with IC50 of 2.2 μM, exhibiting no inhibitory activity on p38, JNK1, ERK1 and -2, PKC, or c-Src-like kinases. This compound upregulates β-catenin and potentiates radiation-induced apoptosis.
|
-
Sci Rep, 2025, 15(1):1973
-
Cell Commun Signal, 2023, 21(1):107
-
Fundam Clin Pharmacol, 2022, 10.1111/fcp.12759
|
|
| S6888 |
SEL201
|
SEL-201 (SLV-2436, SEL201-88) is a highly potent and ATP-competitive inhibitor of MNK1 and MNK2 with IC50 of 10.8 nM and 5.4 nM, respectively.
|
-
Eur J Pharm Sci, 2022, 177:106278
|
|
| S6658 |
ETC-206 (AUM 001)
|
ETC-206 (AUM 001, ETC-1907206) is an orally available highly selective small-molecule MNK 1/2 inhibitor with IC50s of 64 nM and 86 nM, respectively.
|
|
|